Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients

Journal of Diabetes Investigation

Volumn 3, Issue 6, 2012, Pages 503-509

  Kubota, Akira ^a   Maeda, Hajime ^a   Kanamori, Akira ^a   Matoba, Kiyokazu ^a   Jin, Yasuyuki ^a   Minagawa, Fuyuki ^a   Obana, Mitsuo ^a   Iemitsu, Kotaro ^a   Ito, Shogo ^a   Amamiya, Hikaru ^a   Kaneshiro, Mizuki ^a   Takai, Masahiko ^a   Kaneshige, Hideaki ^a   Hoshino, Kazuhiko ^a   Ishikawa, Masashi ^a   Minami, Nobuaki ^a   Takuma, Tetsuro ^a   Sasai, Nobuo ^a   Aoyagi, Sachio ^a   Kawata, Takehiro ^a   Mokubo, Atsuko ^a   Takeda, Hiroshi ^a   Honda, Shin ^a   Machimura, Hideo ^a   Motomiya, Tetsuya ^a   Waseda, Manabu ^a   Naka, Yoshikazu ^a   Tanaka, Yasushi ^b   Terauchi, Yasuo ^c   Matsuba, Ikuro ^a   more..

^a Kanagawa Health Service Association   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Diabetes mellitus; Sitagliptin; Sulfonylurea

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BLOATING; BODY MASS; BODY WEIGHT; CLINICAL PRACTICE; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; JAPANESE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION;

EID: 84871651233     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2012.00221.x     Document Type: Article

References (29)

1. Herman GA, Stein PP, Thornberry NA, et al. Dipeptidyl peptidase-4 inhibitors for the treatment of type2 diabetes: focus on sitagliptin. Clin Pharmacol Ther 2007; 81: 761-767.
2. Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005; 78: 675-688.
3. Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006; 28: 55-72.
4. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type2 diabetes. J Clin Endocrinol Metab 2006; 91: 4612-4619.
5. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: Similarities and differences. J Diabetes Invest 2010; 1: 8-23.
6. Kuroe A, Fukushima M, Usami M, et al. Impaired beta-cell function and insulin sensitivity in Japanese subjects with normal glucose tolerance. Diabetes Res Clin Pract 2003; 59: 71-77.
7. Fukushima M, Usami M, Ikeda M, et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type2 diabetes. Metabolism 2004; 53: 831-835.
8. Yoshinaga H, Kosaka K. Heterogeneous relationship of early insulin response and fasting insulin level with development of non-insulin-dependent diabetes mellitus in non-diabetic Japanese subjects with or without obesity. Diabetes Res Clin Pract 1999; 44: 129-136.
9. Arai K, Matoba K, Hirao K, et al. Present status of sulfonylurea treatment for type2 diabetes in Japan: second report of a cross-sectional survey of 15, 652 patients. Endocr J 2010; 57: 499-507.
10. Iwamoto Y, Taniguchi T, Nonaka K, et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type2 diabetes mellitus. Endocr J 2010; 57: 383-394.
11. Iwamoto Y, Tajima N, Kadowaki T, et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab 2010; 12: 613-622.
12. Jin Y, Kanamori A, Ito S, et al. Cross-sectional survey of diabetic neuropathy in Kanagawa and clinical significance of a touch test using tissue paper. J Diabetes Invest 2012; 3: 252-258.
13. The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino Y, Nanjo K, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest, 2010; 1: 212-228.
14. Esposito K, Cozzolino D, Bellastella G, et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab 2011; 13: 594-603.
15. Maeda H, Kubota A, Tanaka Y, et al. The safety and efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type2 diabetes. Diabetes Res Clin Pract 2012; 95: e20-e22.
16. Nomiyama T, Akehi Y, Takenoshita H, et al. Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type2 diabetes. Diabetes Res Clin Pract 2012; 95: e27-e28.
17. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-3723.
18. Nauck MA, Vardarli I, Deacon CF, et al. Secretion of glucagon-like peptide-1 (GLP-1) in type2 diabetes: what is up, what is down?Diabetologia 2011; 54: 10-18.
19. Yabe D, Kuroe A, Lee S, et al. Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: comparison of type2 diabetes patients and healthy controls. J Diabetes Invest 2010; 1: 56-59.
20. Yamane S, Harada N, Hamasaki A, et al. Effects of glucose and meal ingestion on incretin secretion in Japanese subjects with normal glucose tolerance. J Diabetes Invest 2012; 3: 80-85.
21. Kubota A, Matsuba I, Saito T, et al. Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type2 diabetes mellitus. J Diabetes Invest, 2011; 2: 377-380.
22. Harada N, Hamasaki A, Yamane S, et al. Plasma gastric inhibitory polypeptide and glucagon-like peptide-1 levels after glucose loading are associated with different factors in Japanese subjects. J Diabetes Invest 2011; 2: 193-199.
23. Ahrén B. Gut peptides and type2 diabetes mellitus treatment. Curr Diab Rep 2003; 3: 365-372.
24. Suga S, Kanno T, Nakano K, et al. GLP-I(7-36) amide augments Ba2+ current through L-type Ca2+ channel of rat pancreatic beta-cell in a cAMP-dependent manner. Diabetes 1997; 46: 1755-1760.
25. Mukai E, Fujimoto S, Sato H, et al. Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner. Diabetes 2011; 60: 218-226.
26. Zhang CL, Katoh M, Shibasaki T, et al. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science 2009; 325: 607-610.
27. Shibasaki T, Takahashi H, Miki T, et al. Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proc Natl Acad Sci USA 2007; 104: 19333-19338.
28. Massi-Benedetti M. Glimepiride in type2 diabetes mellitus: a review of the worldwide therapeutic experience. Clin Ther 2003; 25: 799-816.
29. Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type2 diabetes mellitus. Metabolism 2006; 55: S20-S27.